[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100528671":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":152,"collaborators":154,"id":158,"slug":159,"hasResults":160,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":165,"sex":166,"minAge":167,"maxAge":168,"enrollmentInfo":169,"targetDuration":172,"studyType":173,"phases":10,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":191},{"fullName":5,"class":6},"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Asthma patients with different severities",null,"Asthma patients with different severities followed for 5 years. Real-life, antiasthmatic drugs selected by investigators. Clinical, analytical, biomarkers, image techniques",[13],"Drug: Antiasthmatic",{"label":15,"type":10,"description":16,"interventionNames":17},"Severe asthma patients treated with biologics","In follow-up for 3 years and new patients. Real-life, antiasthmatic drugs selected by investigators. Clinical, analytical, biomarkers, image techniques",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Antiasthmatic","real-life",[9,15],[25],"biologics",[27],{"name":28,"affiliation":29,"role":30},"Joaquin Sastre","Fundacion Jimenez Diaz","STUDY_DIRECTOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":10,"email":36},"Joaquin S Sastre","CONTACT","34609835363","jsastre@fjd.es",[38,57,72,86,97,108,123,137],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Hospital Universitario Santiago de Compostela","RECRUITING","Santiago de Compostela","Acoruña","15706","Spain","ES",{"type":47,"coordinates":48},"Point",[49,50],-8.54569,42.88052,{"lat":50,"lon":49},[53],{"name":54,"role":34,"phone":55,"phoneExt":10,"email":56},"FRANCISCO JAVIER GONZALEZ-BARCALA, MD, PhD","+34607 819 141","fjgbarcala@gmail.com",{"facility":58,"status":40,"city":59,"state":60,"zip":61,"country":44,"countryCode":45,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Hospital Universitario Germans Trias","Badalona","BARCELONA","08916",{"type":47,"coordinates":63},[64,65],2.24741,41.45004,{"lat":65,"lon":64},[68],{"name":69,"role":34,"phone":70,"phoneExt":10,"email":71},"CARLOS MARTINEZ-RIVERA, MD, PHD","34934651200","carlosmartinezrivera.cmr@gmail.com",{"facility":73,"status":40,"city":74,"state":60,"zip":75,"country":44,"countryCode":45,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Hospital Universitari Vall de Hebron","Barcelona","08035",{"type":47,"coordinates":77},[78,79],2.15899,41.38879,{"lat":79,"lon":78},[82],{"name":83,"role":34,"phone":84,"phoneExt":10,"email":85},"XAVIER MUÑOZ, MD, PhD","34934 893 000","xavier.munoz@vallhebron.cat",{"facility":87,"status":40,"city":74,"state":60,"zip":88,"country":44,"countryCode":45,"cosmosGeoPoint":89,"geoPoint":91,"contacts":92},"Hospital Clinic","08036",{"type":47,"coordinates":90},[78,79],{"lat":79,"lon":78},[93],{"name":94,"role":34,"phone":95,"phoneExt":10,"email":96},"EBYMAR ARISMENDI, MD, PhD","3493 227 54 00","EARISMEN@clinic.cat",{"facility":98,"status":40,"city":74,"state":60,"zip":99,"country":44,"countryCode":45,"cosmosGeoPoint":100,"geoPoint":102,"contacts":103},"Hospital Universitario Sant Pau","08041",{"type":47,"coordinates":101},[78,79],{"lat":79,"lon":78},[104],{"name":105,"role":34,"phone":106,"phoneExt":10,"email":107},"LORENA SOTO, MD, PhD","3493 556 57 75","LSoto@santpau.cat",{"facility":109,"status":40,"city":110,"state":111,"zip":112,"country":44,"countryCode":45,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Hospital Del Ferrol","A Coruña","LA CORUÑA","15405",{"type":47,"coordinates":114},[115,116],-8.396,43.37135,{"lat":116,"lon":115},[119],{"name":120,"role":34,"phone":121,"phoneExt":10,"email":122},"MANUEL J RIAL, MD, PhD","34 669174538","manuterial@gmail.com",{"facility":124,"status":40,"city":125,"state":125,"zip":126,"country":44,"countryCode":45,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Hospital Universitario La Paz","Madrid","28046",{"type":47,"coordinates":128},[129,130],-3.70256,40.4165,{"lat":130,"lon":129},[133],{"name":134,"role":34,"phone":135,"phoneExt":10,"email":136},"Santiago Quirce, MD, PhD","34 659147570","squirce@gmail.com",{"facility":138,"status":40,"city":139,"state":140,"zip":141,"country":44,"countryCode":45,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"Hospital Universitario de Navarra","Pamplona","Navarre","31008",{"type":47,"coordinates":143},[144,145],-1.64323,42.81687,{"lat":145,"lon":144},[148],{"name":149,"role":34,"phone":150,"phoneExt":10,"email":151},"JOSE MARIA OLAGUIBEL, MD, PhD","34649063064","jm.olaguibel.rivera@navarra.es",{"type":153,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[155],{"name":156,"class":157},"Sanofi","INDUSTRY","100528671","follow-up-of-spanish-prospective-asthma-and-nasal-polyposis-registry-100528671",false,"NCT06163807","Follow-up of Spanish Prospective Asthma and Nasal Polyposis Registry","MEGA","Inclusion Criteria:\n\nFor the general asthma cohort (MEGA):\n\n* Age from 18 to 80 y.o. with asthma with and without nasal polyposis based on GINA guidelines (compatible clinical symptoms+reversibility of at least 12% and 200 mL in FEV1 after the administration of 200-400 μg albuterol\u002Fsalbutamol or positive methacholine test) of several severities attended at participant centres\n* Already in follow-up in MEGA cohort\n* To participate in the study\n* Signed informed consent\n\nInclusion criteria for asthma patients treated with biologics\n\n* Patients from 18 to 80 y.o. with uncontrolled asthma with and without nasal polyposis that fulfil criteria to be treated with biological drugs (Existing treatment with medium-to-high-dose ICS (≥ 250 μg of fluticasone propionate twice daily or equipotent ICS daily dosage to a maximum of 2000 μg\u002Fday of fluticasone propionate or equivalent) in combination with a second controller (e.g., LABA, LTRA) for at least 3 months+ airflow limitation- FEV1 \\\u003C80%\u002FFEV1\u002FFVC \\\u003C70+ACQ-5 score ≥ 1.5\u002F ACT \\\u003C 19 at inclusion and\u002For have experience any of the following events on the last year: treatment with systemic steroids\u002F hospitalization or emergency medical care visit for worsening asthma.\n* When planning dupilumab, mepolizumab, benralizumab or reslizumab, biomarker levels, and exacerbation in the previous year will be considered according to the Spanish Ministry of Health recommendations for reimbursement of any biological drug in severe asthma. In the case of Omalizumab allergic asthma and IgE \\> 75 and \\\u003C 1500 UI\n* Patients already in follow-up in the cohort of patients treated with biologics\n* Willing to participate in the study\n* Sign informed consent\n\nExclusion Criteria:\n\n* Exclusion criteria for MEGA COHORT\n\n  * Diagnosis of chronic obstructive pulmonary disease or other lung disease that may impair lung function\n  * Comorbid disease that might interfere with the evaluation, e.g. psychiatric disorders\n  * Patients participating in other clinical trials\n  * Patients without the capacity to understand the aim of the study\n* Exclusion criteria for asthma patients treated with biologics\n\n  * Diagnosis of chronic obstructive pulmonary disease or other lung disease that may impair lung function\n  * Comorbid disease that might interfere with the evaluation, e.g. psychiatric disorders\n  * Patients participating in other clinical trials\n  * Patients without the capacity to understand the aim of the study",true,"ALL","18 Years","80 Years",{"count":170,"type":171},1200,"ESTIMATED","3 Years","OBSERVATIONAL","Primary objective\n\n\\- To study the stability of different phenotypes and endotypes of asthma at 3, 5, and 7 years of follow-up and - in MEGA COHORT and in patients on biologic treatment\n\nSecondary objective(s)\n\n* To study biomarkers variation post-treatment in patients with and without Nasal Polyposis\n* To demonstrate the existence of different subtypes of eosinophils that may be phenotypically and functionally heterogeneous\n* To increase the number of patients in the cohort on biologic treatment to reach at least 900 (400 over the current cohort).",[176],"Chronic Asthma",[178,25,179,180,181],"asthma","biomarkers","nasal polyposis","eosinophils","2026-03-25",{"date":184,"type":185},"2026-03-30","ACTUAL",{"date":187,"type":185},"2025-02-01",{"date":189,"type":171},"2026-06-02",{"name":5,"class":6},8]